Sahajanand Medical Technologies Limited has announced the outcome of its Board Meeting held on November 5, 2026. The company approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report. Additionally, the Board approved an investment by its wholly-owned subsidiary in SNP Medical Corp., a US-based corporation. The appointment of M/s. Amit Jaste & Associates as Secretarial Auditor for five years was also approved, subject to shareholder approval.
Financial Results Approved
Sahajanand Medical Technologies Limited (SMT) announced today, November 5, 2026, that its Board of Directors has considered and approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Limited Review Report for these financial statements was also approved.
Strategic Investment in US Subsidiary
The Board also gave its approval for an investment by Sahajanand Medical Technologies Ireland Limited, a wholly-owned subsidiary of SMT, into SNP Medical Corp., a US-based corporation registered in Delaware. Further details regarding this acquisition are provided in Annexure A.
Appointment of Secretarial Auditor
Furthermore, SMT has appointed M/s. Amit Jaste & Associates as the Secretarial Auditor for the company. This appointment is for a term of five consecutive financial years, commencing from FY 2026-27 to FY 2030-31. The appointment is subject to the approval of the company’s shareholders. Details of the appointment are outlined in Annexure B.
Meeting Details
The Board meeting commenced at 3:00 PM (IST) and concluded at 4:43 PM (IST) on November 5, 2026. The intimation of these outcomes is available on the websites of the company (www.smtpl.com) and the stock exchanges (BSE and NSE).
Source: BSE
